An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus

January 4, 2016 updated by: Zafgen, Inc.

Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of ZGN-440 (Subcutaneous Beloranib in Suspension) in Obese Subjects With Type 2 Diabetes Mellitus to Evaluate Weight Reduction, Glycemic Control, Safety, and Tolerability

The purpose of this study is to evaluate efficacy and safety of ZGN-440 (beloranib) in obese adult subjects with type 2 diabetes mellitus.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

Phase 2, randomized, double-blind, placebo-controlled, parallel dose arms study with 12-month randomized treatment.

Study Type

Interventional

Enrollment (Actual)

152

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Australia
    • New South Wales
      • Camperdown, New South Wales, Australia, 2050
        • Royal Prince Alfred Hospital
      • Cardiff, New South Wales, Australia, 2285
        • Pendlebury Research
      • Maroubra, New South Wales, Australia, 2035
        • Australian Clinical Research Network
      • St. Leonards, New South Wales, Australia, 2065
        • Royal North Shore Hospital
      • Wollongong, New South Wales, Australia, 2500
        • Illawara Diabetes Service
    • Queensland
      • Herston, Queensland, Australia, 4006
        • Q-Pharm
      • Ipswich, Queensland, Australia, 4305
        • Ipswich Research Institute
      • Sherwood, Queensland, Australia, 4075
        • AusTrials
    • South Australia
      • Adelaide, South Australia, Australia, 5000
        • CMAX
    • Victoria
      • Box Hill, Victoria, Australia, 3128
        • Box Hill Hospital
      • Fitzroy, Victoria, Australia, 3065
        • St. Vincent's Hospital
      • Geelong, Victoria, Australia, 3220
        • Barwon Health
      • Heidelberg West, Victoria, Australia, 3081
        • Austin Health
      • Malvern East, Victoria, Australia, 3145
        • Emeritus Research
      • Melbourne, Victoria, Australia, 3004
        • Baker IDI Heart and Diabetes Institute
    • Western Australia
      • Nedlands, Western Australia, Australia, 6009
        • Keogh Institute for Medical Research

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Obese with BMI ≥30 kg/m2
  • Type 2 diabetes mellitus
  • HbA1c of 7-11%
  • Fasting glucose <15.5 mmol/L
  • Treated with diet and exercise alone or with a stable regimen of metformin, sulfonylurea, pioglitazone, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT-2 inhibitor or any combination of these agents
  • Female subjects must be surgically sterile, post-menopausal or using long-acting contraception, which includes intrauterine devices or use of an implanted or injectable contraceptive

Exclusion Criteria:

  • Current or recent use of insulin
  • Severe hypoglycemia within the prior 6 months
  • Metabolic disorders or genetic disorders linked to obesity (e.g., Prader-Willi Syndrome)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ZGN-440 Injectable Suspension (1.2mg)
ZGN-440 for Injectable Suspension
Drug: ZGN-440 for Injectable Suspension
Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 52 weeks.
Other Names:
  • ZGN-440
  • Beloranib
Experimental: ZGN-440 Injectable Suspension (1.8mg)
ZGN-440 for Injectable Suspension
Drug: ZGN-440 for Injectable Suspension
Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 52 weeks.
Other Names:
  • ZGN-440
  • Beloranib
Placebo Comparator: Placebo
ZGN-440 Placebo for Injectable Suspension
Drug: ZGN-440 Placebo for Injectable Suspension
Subjects will receive placebo twice weekly subcutaneous injections for up to 52 weeks.
Other Names:
  • Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change in body weight
Time Frame: Baseline to Week 26
Baseline to Week 26
Safety and tolerability assessed by adverse events, laboratory evaluations, ECGs, vital signs, physical examinations
Time Frame: Baseline to Week 26 and Week 52
Baseline to Week 26 and Week 52

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in body weight
Time Frame: Baseline to Week 52
Baseline to Week 52
Change in fasting glycemic parameters
Time Frame: Baseline to Week 26 and Week 52
HbA1c, plasma glucose
Baseline to Week 26 and Week 52
Change in cardiometabolic parameters
Time Frame: Baseline to Week 26 and Week 52
Blood pressure, lipid concentrations, hs-CRP
Baseline to Week 26 and Week 52
Change in Patient Reported Outcomes (PRO) scores
Time Frame: Baseline to Week 26 and Week 52
Baseline to Week 26 and Week 52

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Zafgen, Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2014

Primary Completion (Actual)

December 1, 2015

Study Completion (Actual)

December 1, 2015

Study Registration Dates

First Submitted

December 18, 2014

First Submitted That Met QC Criteria

December 23, 2014

First Posted (Estimate)

December 24, 2014

Study Record Updates

Last Update Posted (Estimate)

January 6, 2016

Last Update Submitted That Met QC Criteria

January 4, 2016

Last Verified

January 1, 2016

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ZAF-203

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on ZGN-440 for Injectable Suspension

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe